INT105222

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.54
First Reported 2002
Last Reported 2011
Negated 1
Speculated 1
Reported most in Body
Documents 18
Total Number 24
Disease Relevance 8.52
Pain Relevance 3.50

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Plau) signal transduction (Plau) extracellular space (Plau)
extracellular region (Plau) kinase activity (Plau)
Anatomy Link Frequency
sciatic nerve 2
neuron 1
node 1
dorsal root ganglia 1
lungs 1
Plau (Rattus norvegicus)
Pain Link Frequency Relevance Heat
cocaine 7 99.98 Very High Very High Very High
Morphine 9 99.60 Very High Very High Very High
Peripheral nerve injury 7 99.40 Very High Very High Very High
Sciatic nerve 59 98.28 Very High Very High Very High
palliative 9 97.88 Very High Very High Very High
Neuropathic pain 5 95.60 Very High Very High Very High
endometriosis 3 93.28 High High
methotrexate 4 92.32 High High
long-term potentiation 2 92.16 High High
Dorsal horn 10 89.12 High High
Disease Link Frequency Relevance Heat
Breast Cancer 29 99.64 Very High Very High Very High
Nervous System Injury 8 99.40 Very High Very High Very High
Advanced Or Metastatic Breast Cancer 4 99.28 Very High Very High Very High
Cancer 22 99.14 Very High Very High Very High
Disease 25 98.04 Very High Very High Very High
Nociception 2 97.84 Very High Very High Very High
Recurrence 8 97.72 Very High Very High Very High
Hyperoxia 1 96.20 Very High Very High Very High
Neuropathic Pain 5 95.60 Very High Very High Very High
Adhesions 8 93.76 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We found the induction of mRNAs for tissue type plasminogen activator (tPA) and urokinase plasminogen activator (uPA) in the rat dorsal root ganglia following sciatic nerve transection.
Positive_regulation (induction) of urokinase plasminogen activator in sciatic nerve associated with sciatic nerve
1) Confidence 0.54 Published 2004 Journal Eur. J. Neurosci. Section Abstract Doc Link 14750967 Disease Relevance 0.47 Pain Relevance 0.55
We found the induction of mRNAs for tissue type plasminogen activator (tPA) and urokinase plasminogen activator (uPA) in the rat dorsal root ganglia following sciatic nerve transection.
Positive_regulation (induction) of uPA in sciatic nerve associated with sciatic nerve
2) Confidence 0.54 Published 2004 Journal Eur. J. Neurosci. Section Abstract Doc Link 14750967 Disease Relevance 0.47 Pain Relevance 0.55
The dynamic induction of gelatinase, TGF-beta, and uPA activities seen in neonatal lungs during the first days of life was significantly impacted by hyperoxia.
Positive_regulation (induction) of uPA in lungs associated with hyperoxia
3) Confidence 0.52 Published 2002 Journal Am. J. Physiol. Lung Cell Mol. Physiol. Section Abstract Doc Link 12225951 Disease Relevance 0.10 Pain Relevance 0.04
The hypothesis of this study was that EPC devices increase the level of urokinase plasminogen activator (uPA), a second activator of fibrinolysis.
Positive_regulation (increase) of uPA
4) Confidence 0.47 Published 2002 Journal J. Vasc. Surg. Section Abstract Doc Link 12422101 Disease Relevance 0.25 Pain Relevance 0.05
Therefore, danshen and tanshinone IIA-enhanced uPA activity using FGF2 might mediate through the JNK and ERK signaling pathways.
Positive_regulation (enhanced) of uPA
5) Confidence 0.29 Published 2011 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2997511 Disease Relevance 0 Pain Relevance 0
In our results, danshen and tanshinone IIA-treated Schwann cells demonstrated dose-dependently increased growth rate (Figures 2(a)–2(c)), protein levels of FGF-2, its downstream JNK, ERK and even P38 signaling, and uPA activity with inhibited PAI-1 and the activation of cyclin D, E and B (Figures 3(a)-3(b) and Figures 4(a)–4(c)) at lower doses of two components, indicating that danshen and tanshinone IIA sufficiently enhance the potential of Schwann cell proliferation for neuron regeneration.
Positive_regulation (increased) of uPA in neuron
6) Confidence 0.29 Published 2011 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2997511 Disease Relevance 0 Pain Relevance 0
As shown in Figure 3(a), representing the protein level results, administration of danshen and tanshinone IIA increased the level of FGF-2, MMP 9, and uPA but decreased the level of PAI-1.
Positive_regulation (increased) of uPA
7) Confidence 0.29 Published 2011 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2997511 Disease Relevance 0.07 Pain Relevance 0
Danshen activated the FGF-signaling pathway as evidenced by increased levels of FGF-2 and uPA.
Positive_regulation (levels) of uPA
8) Confidence 0.27 Published 2011 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2997511 Disease Relevance 0 Pain Relevance 0.05
FGF is one of the mediators of uPA activity [22–24].
Positive_regulation (mediators) of uPA
9) Confidence 0.27 Published 2011 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2997511 Disease Relevance 0.26 Pain Relevance 0.03
Danshen activated the FGF-signaling pathway as evidenced by increased levels of FGF-2 and uPA.
Positive_regulation (increased) of uPA
10) Confidence 0.27 Published 2011 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2997511 Disease Relevance 0 Pain Relevance 0.05
In metastatic breast cancer, retrospective studies showed that elevated uPA or PAI-1 present in the primary tumor tissue are associated with a poor response to later palliative endocrine therapy.
Positive_regulation (elevated) of uPA associated with cancer, advanced or metastatic breast cancer and palliative
11) Confidence 0.26 Published 2004 Journal Clin. Breast Cancer Section Abstract Doc Link 15585071 Disease Relevance 1.17 Pain Relevance 0.21
Visual analog pain score reduction correlated with changes in uPA and uPAR levels as well as uPA activity.
Positive_regulation (changes) of uPA
12) Confidence 0.23 Published 2010 Journal Oral Surg Oral Med Oral Pathol Oral Radiol Endod Section Body Doc Link 20185343 Disease Relevance 0.11 Pain Relevance 0
Visual analog pain score reduction correlated with changes in uPA and uPAR levels as well as uPA activity.
Positive_regulation (changes) of uPA
13) Confidence 0.23 Published 2010 Journal Oral Surg Oral Med Oral Pathol Oral Radiol Endod Section Body Doc Link 20185343 Disease Relevance 0.11 Pain Relevance 0
RESULTS: The OA patients had significantly higher uPA activity and levels of uPA (median 80.01 ng/L), suPAR (median 7.54 ng/L), and PAI-1 (median 54.9 ng/mL) than the healthy control subjects (median 20.47 ng/L uPA, 2.34 ng/L suPAR, and 19.9 ng/mL PAI-1; (P < .05).
Positive_regulation (activity) of uPA
14) Confidence 0.22 Published 2010 Journal Oral Surg Oral Med Oral Pathol Oral Radiol Endod Section Body Doc Link 20185343 Disease Relevance 0.14 Pain Relevance 0
RESULTS: The OA patients had significantly higher uPA activity and levels of uPA (median 80.01 ng/L), suPAR (median 7.54 ng/L), and PAI-1 (median 54.9 ng/mL) than the healthy control subjects (median 20.47 ng/L uPA, 2.34 ng/L suPAR, and 19.9 ng/mL PAI-1; (P < .05).
Positive_regulation (activity) of uPA
15) Confidence 0.22 Published 2010 Journal Oral Surg Oral Med Oral Pathol Oral Radiol Endod Section Body Doc Link 20185343 Disease Relevance 0.14 Pain Relevance 0
RESULTS: The OA patients had significantly higher uPA activity and levels of uPA (median 80.01 ng/L), suPAR (median 7.54 ng/L), and PAI-1 (median 54.9 ng/mL) than the healthy control subjects (median 20.47 ng/L uPA, 2.34 ng/L suPAR, and 19.9 ng/mL PAI-1; (P < .05).
Positive_regulation (higher) of uPA
16) Confidence 0.22 Published 2010 Journal Oral Surg Oral Med Oral Pathol Oral Radiol Endod Section Body Doc Link 20185343 Disease Relevance 0.14 Pain Relevance 0
However, benefit from adjuvant endocrine therapy appears to be independent of a patient's uPA/PAI-1 status.
Neg (independent) Spec (appears) Positive_regulation (independent) of uPA
17) Confidence 0.19 Published 2004 Journal Clin. Breast Cancer Section Abstract Doc Link 15585071 Disease Relevance 1.21 Pain Relevance 0.20
Patients with node-negative breast cancer with low antigen levels of uPA and PAI-1 in their primary tumor tissue have a very good prognosis and therefore may be spared the burden of adjuvant chemotherapy, whereas those with elevated uPA/PAI-1 antigen levels carry an increased risk of disease recurrence.
Positive_regulation (elevated) of uPA in node associated with cancer, breast cancer, disease and recurrence
18) Confidence 0.19 Published 2004 Journal Clin. Breast Cancer Section Abstract Doc Link 15585071 Disease Relevance 1.18 Pain Relevance 0.03
These findings suggest that high levels of uPA and/or PAI-1 do reflect an aggressive phenotype that may be overcome or suppressed by early systemic therapy in the adjuvant setting but may be too advanced for response to palliative therapy at a later stage.
Positive_regulation (levels) of uPA associated with palliative
19) Confidence 0.19 Published 2004 Journal Clin. Breast Cancer Section Abstract Doc Link 15585071 Disease Relevance 0.94 Pain Relevance 0.23
Psychostimulants induce both tPA and uPA in acute and chronic drug delivery, but cocaine induces preferentially uPA, whereas morphine and amphetamine induce preferentially tPA.
Positive_regulation (induce) of uPA associated with morphine and cocaine
20) Confidence 0.14 Published 2008 Journal Genes Brain Behav. Section Abstract Doc Link 17680802 Disease Relevance 0 Pain Relevance 0.44

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox